Recent News
Many of the common symptoms of lupus - fatigue, nociplastic pain, brain fog - can be invisible and difficult to measure, and can often co-occur with impaired sleep, depression and anxiety. These symptoms have led to a well described discordance between physician and patient perception of lupus activity and flares, and this discordance can impact communication, trust, medication adherence, and ultimately outcomes. We developed the Type 1 and Type 2 model many years ago as a means to bridge this gap, and to incorporate these type 2 symptoms as intrinsic features of lupus and autoimmunity with perhaps a mixed or less clear relationship to inflammation.Read Article
PPACMAN Consensus Recs. for CV risk in PSO/PSA published for Rheums/Derms/PCPs
- check BP, Wt, Lipids, Cr.
- Look for HTN, DM, smoking, obesity, metabolic synd.
- Risk stratify w/ hsCRP, Lipids
- Lifestyle management https://t.co/MkgYopTNAX https://t.co/6yyxVIxpC0
Dr. John Cush @RheumNow ( View Tweet)
Review of ARF & Post-streptococcal reactive arthritis (PSRA) following Group A strept infxn. Early Dx & Rx of Strept can prevent ARF & PSRA. PSRA is a sterile arthritis, bimodal age onset, lower extrem arthritis, usually resolves without lasting sequelae https://t.co/ld208yf0Zk
Links:
Dr. John Cush @RheumNow ( View Tweet)
NEW ACR 2024 POSTER: Phase 3 KEEPsAKE 1 and 2 post hoc analyses of time to first response with an IL-23i
View the latest data on time to first efficacy responses and PROs in patients with active PsA. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/3QTurnvokp https://t.co/xnjma7AsTA
Dr. John Cush @RheumNow ( View Tweet)
JAK inhibitors reduce inflammation while potentially exacerbating the propagation viral infections. They suppress transcription of IFN-stimulated genes in non-infected cells (usually triggered by type I IFNs produced by infected cells) Thus facilitating viral propagation https://t.co/zOOTf7e1Hj
Dr. John Cush @RheumNow ( View Tweet)
MMWR: 1994 the U.S. Vaccines for Children program has covered the cost of vaccines for US children. Since 1994 routine child vaccinations will have prevented ~508 million illness, 32 million hospitalizations, & 1,129,000 deaths,; direct savings of $540 billion & societal savings https://t.co/CBUojpR3Q8
Dr. John Cush @RheumNow ( View Tweet)
Denosumab and Osteoporosis - A JAMA Review
An overview of denosumab use in osteoporosis (OP) by Bauer and Ensrud was published in JAMA.
Read Article
Rules on Mycophenolate Use in SLE
Dr. Diane Kamen. a rheumatologist and lupologist from the Medical University of South Carolina in Charleston, South Carolina, discusses the use of mychophenolate in the management of systemic lupus.
Read Article
Single center study of 1538 #SLE pts found 2.2% w/ lupus mesenteric vasculitis (LMV) - 39 LMV episodes in 31 pts - 2/3 had Nausea, vomiting, diarrhea & abdominal pain (~15% peritoneal irritation) & had active Dz (renal, Skin, Heme). LMV responded to steroids & https://t.co/vXCpbiC60P
Dr. John Cush @RheumNow ( View Tweet)
Lupus Unlocked: Survey Responses
https://t.co/LQs7VKT6lq https://t.co/F7yqQvSvvZ
Dr. John Cush @RheumNow ( View Tweet)
CNS Lupus (NPSLE)
https://t.co/912jnMSr5F https://t.co/LQGDgXe4gi
Links:
Dr. John Cush @RheumNow ( View Tweet)
Lupus Unlocked: Pregnancy and SLE
In this webinar, panelists discussed issues such as congenital heart block, lupus nephritis treatment, teratogenic risks including conception on mycophenolate, antiphospholipid syndrome, hypertension management including the differential https://t.co/0RfAH7jW0J
Dr. John Cush @RheumNow ( View Tweet)
Are PSO pts also Rx for PSA? Registry study of 17,310 PSO pts (19% also w PsA). @ baseline Biologics used in 44% of PSO, but higher rate in PSO+PsA (66% vs 39% PSO). 9.4% of PSO+PsA pts on Rx approved for PSO, but not explicitly for PsA. https://t.co/jMqk6gm1RR https://t.co/CQnwYO9yRO
Links:
Dr. John Cush @RheumNow ( View Tweet)
Do SGLT2 and GLP-1 therapies have a role in Lupus?
Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i) and Glucagon-like peptide-1 receptor agonists (GLP1-RA), initially developed to lower glucose in Type 2 Diabetes, also provide cardiovascular and renal protection for patients https://t.co/8JEfcv2BUz
Dr. John Cush @RheumNow ( View Tweet)
Belimumab in SLE with Mucocutaneous or Vasculitis Findings
A post hoc analysis of a belimumab (BEL) inn systemic lupus erythematosus (SLE) study showed lupus mucocutaneous and vasculitic manifestations improve with BEL and standard care.
https://t.co/BlYWKLJPdb
Dr. John Cush @RheumNow ( View Tweet)
Valves Gone Wild in SLE
Lupus valvulitis is a rare cardiac manifestation of active systemic lupus erythematosus (SLE) and is defined by inflammation of one or more cardiac valves. It is often associated with Libman-Sacks endocarditis (LSE), which is characterized by the https://t.co/XcC2POFDRd
Dr. John Cush @RheumNow ( View Tweet)
2025 ACR Guideline for the Treatment of SLE
The ACR has released its 2025 Systemic Lupus Erythematosus (SLE) treatment guidelines and consensus-based good practice statements, applicable to children and adults with SLE.
https://t.co/2NFwTllLZa https://t.co/Q6smp1ZVH2
Dr. John Cush @RheumNow ( View Tweet)
IMPACT Study - Certolizumab Efficacy in APS Pregnancies
A pilot trial assessed the safety and value of tumour necrosis factor α inhibitor treatment with certolizumab in patients with high-risk pregnancies with antiphospholipid syndrome (APS). Certolizumab (CZP) was shown to https://t.co/776CTvvGfb
Dr. John Cush @RheumNow ( View Tweet)
Shifting the Management Paradigm for SLE and Lupus Nephritis
The paradigm for treating patients with systemic lupus erythematosus (SLE) is rapidly shifting and our patients will surely benefit with improved outcomes.
https://t.co/idxMBTyTwp https://t.co/f5G3cFb3XK
Dr. John Cush @RheumNow ( View Tweet)
QUOTES TO LIVE BY: "it took me a long time be a good listener and be comfortable with silence. Its important to not just throwing facts back to patients who are suffering.
Sometimes pausing is powerful. Its all about establishing relationships " - Dr. Len Calabrese https://t.co/wcKX8nTa2o
Dr. John Cush @RheumNow ( View Tweet)
Hydroxychloroquine: Are Your Patients Taking It?
Dr. Nathalie Costedoat-Chalumeau dives into monitoring HCQ levels and what they tell us about patient adherence.
💡Learn how to spot non-compliance early.
👉 Now live on RheumNow: https://t.co/KPjyCrMTBr
#LupusCare https://t.co/vRASCc9kB0
Links:
Dr. John Cush @RheumNow ( View Tweet)
From the blog
Podcasts
Moneyball Rheumatology
Rx Update - Lupus Nephritis
Lupus Unlocked- Pregnancy and SLE
Lupus QD Clinics - lessons from the Clinic - Week 3
Therapeutic Updates
Debunked. Expert perspectives on Sjögren’s Disease myths
Sponsored by Novartis Medical Affairs
How well do you know Sjögren’s disease? Test your knowledge and then hear rheumatologist, Dr Sara McCoy, discuss common myths and realities about managing patients with Sjögren’s disease.
Read Post
Patient Phenotypes Within the Clinical Program of an IL-23 Inhibitor for PsA
Sponsored by AbbVie Medical Affairs + Health Impact
Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and
dermatologist Dr. Saakshi Khattri discuss a new analysis of patient
phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this
conversation, they discuss disease activity differences between
clinical trial populations and real-world patients, efficacy of an IL-23
inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23
inhibitor's potential role in managing patients with PsA.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
Long-term maintenance of response of an IL-23i in PsA
Daily Gem
PETRI-isms: "The patient is always right (even when they are wrong)." - Dr. Michelle Petri
--